Northwest Biotherapeutics

Northwest Biotherapeutics (NWBO) announced the passing of Senior Vice President and General Counsel, Les Goldman. Goldman was a key contributor to NWBO, a biotech firm focused on personalized immune therapies for solid tumor cancers, particularly via its DCVax® platform. NWBO is advancing DCVax®-L for glioblastoma, with UK regulatory review underway. They are also developing DCVax®-Direct for inoperable solid tumors. His responsibilities are being assumed by existing management.